Issues and trends in pediatric growth hormone therapy - An update from the GHMonitorSM observational registry

Pisit Pitukcheewanont, Paul Desrosiers, Joel Steelman, Robert Rapaport, John Fuqua, Nerissa C. Kreher, Anthony Hamlett

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The GHMonitorSM observational registry collates data on pediatric subjects receiving Saizen® (recombinant human growth hormone (GH)) therapy. From January 2003 through August 2006, 1335 subjects were enrolled in the registry, approximately two-thirds of whom are male. The most common diagnosis in the registry is idiopathic growth hormone deficiency (58%). Most subjects in GHMonitorSM are receiving Saizen® doses using a needle-free delivery device, the cool.click® (73%). Mean height standard deviation scores show an improvement from -2.1 at screening to -1.1 following 3 years of Saizen® therapy. To date, adverse events have been reported in 4% of subjects. Three serious adverse events were identified to be related to Saizen® by the primary investigator: cellulitis at the injection site, behavioral problems/suicidal ideation, and enlargement of a craniopharyngioma. This article provides an update on data from the registry and briefly discusses topical and controversial issues in the treatment of pediatric patients requiring GH therapy.

Original languageEnglish
Pages (from-to)702-707
Number of pages6
JournalPediatric Endocrinology Reviews
Volume5
Issue numberSUPPL. 2
StatePublished - Feb 2008

Fingerprint

Human Growth Hormone
Growth Hormone
Registries
Pediatrics
Therapeutics
Craniopharyngioma
Suicidal Ideation
Cellulitis
Needles
Research Personnel
Equipment and Supplies
Injections

Keywords

  • Body mass index
  • Dose
  • GHMonitor
  • Gonadotropin releasing-hormone agonist
  • Growth hormone
  • Growth hormone deficiency
  • Insulin-like growth factor-I
  • Neuroimaging

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

Pitukcheewanont, P., Desrosiers, P., Steelman, J., Rapaport, R., Fuqua, J., Kreher, N. C., & Hamlett, A. (2008). Issues and trends in pediatric growth hormone therapy - An update from the GHMonitorSM observational registry. Pediatric Endocrinology Reviews, 5(SUPPL. 2), 702-707.

Issues and trends in pediatric growth hormone therapy - An update from the GHMonitorSM observational registry. / Pitukcheewanont, Pisit; Desrosiers, Paul; Steelman, Joel; Rapaport, Robert; Fuqua, John; Kreher, Nerissa C.; Hamlett, Anthony.

In: Pediatric Endocrinology Reviews, Vol. 5, No. SUPPL. 2, 02.2008, p. 702-707.

Research output: Contribution to journalArticle

Pitukcheewanont, P, Desrosiers, P, Steelman, J, Rapaport, R, Fuqua, J, Kreher, NC & Hamlett, A 2008, 'Issues and trends in pediatric growth hormone therapy - An update from the GHMonitorSM observational registry', Pediatric Endocrinology Reviews, vol. 5, no. SUPPL. 2, pp. 702-707.
Pitukcheewanont P, Desrosiers P, Steelman J, Rapaport R, Fuqua J, Kreher NC et al. Issues and trends in pediatric growth hormone therapy - An update from the GHMonitorSM observational registry. Pediatric Endocrinology Reviews. 2008 Feb;5(SUPPL. 2):702-707.
Pitukcheewanont, Pisit ; Desrosiers, Paul ; Steelman, Joel ; Rapaport, Robert ; Fuqua, John ; Kreher, Nerissa C. ; Hamlett, Anthony. / Issues and trends in pediatric growth hormone therapy - An update from the GHMonitorSM observational registry. In: Pediatric Endocrinology Reviews. 2008 ; Vol. 5, No. SUPPL. 2. pp. 702-707.
@article{774758bab44545f6b5b4c3753bc3a2ff,
title = "Issues and trends in pediatric growth hormone therapy - An update from the GHMonitorSM observational registry",
abstract = "The GHMonitorSM observational registry collates data on pediatric subjects receiving Saizen{\circledR} (recombinant human growth hormone (GH)) therapy. From January 2003 through August 2006, 1335 subjects were enrolled in the registry, approximately two-thirds of whom are male. The most common diagnosis in the registry is idiopathic growth hormone deficiency (58{\%}). Most subjects in GHMonitorSM are receiving Saizen{\circledR} doses using a needle-free delivery device, the cool.click{\circledR} (73{\%}). Mean height standard deviation scores show an improvement from -2.1 at screening to -1.1 following 3 years of Saizen{\circledR} therapy. To date, adverse events have been reported in 4{\%} of subjects. Three serious adverse events were identified to be related to Saizen{\circledR} by the primary investigator: cellulitis at the injection site, behavioral problems/suicidal ideation, and enlargement of a craniopharyngioma. This article provides an update on data from the registry and briefly discusses topical and controversial issues in the treatment of pediatric patients requiring GH therapy.",
keywords = "Body mass index, Dose, GHMonitor, Gonadotropin releasing-hormone agonist, Growth hormone, Growth hormone deficiency, Insulin-like growth factor-I, Neuroimaging",
author = "Pisit Pitukcheewanont and Paul Desrosiers and Joel Steelman and Robert Rapaport and John Fuqua and Kreher, {Nerissa C.} and Anthony Hamlett",
year = "2008",
month = "2",
language = "English",
volume = "5",
pages = "702--707",
journal = "Pediatric Endocrinology Reviews",
issn = "1565-4753",
publisher = "YS Medical Media Ltd.",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Issues and trends in pediatric growth hormone therapy - An update from the GHMonitorSM observational registry

AU - Pitukcheewanont, Pisit

AU - Desrosiers, Paul

AU - Steelman, Joel

AU - Rapaport, Robert

AU - Fuqua, John

AU - Kreher, Nerissa C.

AU - Hamlett, Anthony

PY - 2008/2

Y1 - 2008/2

N2 - The GHMonitorSM observational registry collates data on pediatric subjects receiving Saizen® (recombinant human growth hormone (GH)) therapy. From January 2003 through August 2006, 1335 subjects were enrolled in the registry, approximately two-thirds of whom are male. The most common diagnosis in the registry is idiopathic growth hormone deficiency (58%). Most subjects in GHMonitorSM are receiving Saizen® doses using a needle-free delivery device, the cool.click® (73%). Mean height standard deviation scores show an improvement from -2.1 at screening to -1.1 following 3 years of Saizen® therapy. To date, adverse events have been reported in 4% of subjects. Three serious adverse events were identified to be related to Saizen® by the primary investigator: cellulitis at the injection site, behavioral problems/suicidal ideation, and enlargement of a craniopharyngioma. This article provides an update on data from the registry and briefly discusses topical and controversial issues in the treatment of pediatric patients requiring GH therapy.

AB - The GHMonitorSM observational registry collates data on pediatric subjects receiving Saizen® (recombinant human growth hormone (GH)) therapy. From January 2003 through August 2006, 1335 subjects were enrolled in the registry, approximately two-thirds of whom are male. The most common diagnosis in the registry is idiopathic growth hormone deficiency (58%). Most subjects in GHMonitorSM are receiving Saizen® doses using a needle-free delivery device, the cool.click® (73%). Mean height standard deviation scores show an improvement from -2.1 at screening to -1.1 following 3 years of Saizen® therapy. To date, adverse events have been reported in 4% of subjects. Three serious adverse events were identified to be related to Saizen® by the primary investigator: cellulitis at the injection site, behavioral problems/suicidal ideation, and enlargement of a craniopharyngioma. This article provides an update on data from the registry and briefly discusses topical and controversial issues in the treatment of pediatric patients requiring GH therapy.

KW - Body mass index

KW - Dose

KW - GHMonitor

KW - Gonadotropin releasing-hormone agonist

KW - Growth hormone

KW - Growth hormone deficiency

KW - Insulin-like growth factor-I

KW - Neuroimaging

UR - http://www.scopus.com/inward/record.url?scp=41549102878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41549102878&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 702

EP - 707

JO - Pediatric Endocrinology Reviews

JF - Pediatric Endocrinology Reviews

SN - 1565-4753

IS - SUPPL. 2

ER -